ERKEKOĞLU, Ü. P. Et Al. 2008. The toxicological evaluation of rimonabant, taranabant, surinabant and otenabant in the treatment of obesity: Why the trials on endocannabinoid receptor antagonists and inverse agonists are suspended?. Fabad Journal of Pharmaceutical Sciences , vol.33, no.2 , 95-108.

ERKEKOĞLU, Ü. P., Giray, B., & Şahin, G., (2008). The toxicological evaluation of rimonabant, taranabant, surinabant and otenabant in the treatment of obesity: Why the trials on endocannabinoid receptor antagonists and inverse agonists are suspended?. Fabad Journal of Pharmaceutical Sciences , vol.33, no.2, 95-108.

ERKEKOĞLU, ÜLFET, BELMA GÜMÜŞEL, And Gönül Şahin. "The toxicological evaluation of rimonabant, taranabant, surinabant and otenabant in the treatment of obesity: Why the trials on endocannabinoid receptor antagonists and inverse agonists are suspended?," Fabad Journal of Pharmaceutical Sciences , vol.33, no.2, 95-108, 2008

ERKEKOĞLU, ÜLFET P. Et Al. "The toxicological evaluation of rimonabant, taranabant, surinabant and otenabant in the treatment of obesity: Why the trials on endocannabinoid receptor antagonists and inverse agonists are suspended?." Fabad Journal of Pharmaceutical Sciences , vol.33, no.2, pp.95-108, 2008

ERKEKOĞLU, Ü. P. Giray, B. And Şahin, G. (2008) . "The toxicological evaluation of rimonabant, taranabant, surinabant and otenabant in the treatment of obesity: Why the trials on endocannabinoid receptor antagonists and inverse agonists are suspended?." Fabad Journal of Pharmaceutical Sciences , vol.33, no.2, pp.95-108.

@article{article, author={ÜLFET PINAR ERKEKOĞLU Et Al. }, title={The toxicological evaluation of rimonabant, taranabant, surinabant and otenabant in the treatment of obesity: Why the trials on endocannabinoid receptor antagonists and inverse agonists are suspended?}, journal={Fabad Journal of Pharmaceutical Sciences}, year=2008, pages={95-108} }